Jbog, I could have made the same argument for Lovenox seeing as how I am very familiar with anticoagulants in the pharmaceutical arena. SNY had great relationships and built lovenox into a multi billion dollar drug with it's multiple indications, large hospital and office based sales forces. Not to mention a successful business model that helped elevate Lovenox to be an exceptional revenue driver in the hospital.
So the argument that Teva won't give up that easy is probably going to be relatively the same as SNY. Now they could surprise us and try to undercut the generic price significantly. Sanofi was successful with their plan to keep lovenox as a sole source in hospitals and that has lasted almost 6 months.
At somepoint m-cop will erode away at Copaxone once approved. There isn't anything big bad TEVA and their relationships can do.
Market Data 
Markets 
AI
